Inside Congress' priorities heading into 2026

Rep. Jeff Van Drew (R-N.J.) discussed congressional priorities for 2026 in an appearance on Fox Report, outlining hopes for the House of Representatives as the new year approaches. The piece provides no specific policy details or fiscal metrics, leaving implications for markets and sector-specific regulation uncertain absent further announcements.

Analysis

Market-structure: An election-year Congress setting priorities for 2026 skews toward beneficiaries of headline fiscal packages — defense (LMT, RTX, GD), infrastructure and materials (NUE, VMC), and select energy names (XOM, CVX) — as near-term procurement and construction appetite typically lifts order books by mid-single digits within 6–18 months. Conversely, sectors facing regulatory focus (large-cap tech: GOOGL, META) and pharma/biotech (PFE, IBB) face compressed multiples from pricing and antitrust proposals; expect 5–20% relative valuation moves if substantive bills advance to markup.

Risk assessment: Tail risks include legislative gridlock (no fiscal boost) or sweeping reform (drug pricing/antitrust) that can cause 20–40% swings in individual names; market moves will cluster around 30–90 day committee votes and CBO scoring releases. Immediate (days) volatility will hinge on headlines; short-term (weeks–months) outcomes depend on Senate math and mid-year budget ceilings; long-term (quarters–years) impacts map to enacted spending and Fed rate response via higher deficits. Hidden dependencies include Treasury issuance and Fed reaction — a >25bp move up in 10yr yields materially shifts the profitability of leveraged cyclicals.

Trade implications: Favor 2–3% long allocations to LMT and RTX funded by 1–2% shorts in biotech ETF IBB or single-name PFE if pricing reform language solidifies; add 3–6 month call spreads on LMT (one-to-two notch OTM) and 3–6 month put spreads on IBB to limit premium. Reduce duration exposure if Congress signals >$200bn incremental deficit risk: trim 5–10yr Treasury exposure to <5% of fixed income sleeve and rotate 2–5% into TIPS or short-dated bills.

Contrarian angles: Markets may be underpricing materials/defense upside because consensus assumes gridlock; a narrow path to passage could produce 5–15% outperformance for cyclical midcaps over 6–12 months. Conversely, a modest biotech sell-off on headline risk could create buying windows for high-quality pharma (JNJ) if legislative language lacks enforcement teeth. Key triggers to watch in next 30–90 days: committee markups, CBO cost estimates, and changes in Senate majority projections — use these as explicit entry/exit signals.

Key Decisions for Investors

• Establish 2–3% long positions split between LMT (Lockheed Martin) and RTX (RTX Corp) over the next 30 trading days; hedge with 1–2% notional 3–6 month OTM call spreads (sell nearer-term call, buy farther OTM) to cap premium and target 10–18% upside.
• Initiate a 1–2% short position in IBB (SPDR S&P Biotech ETF) or a 1% short of PFE if legislative language explicitly includes drug price negotiation in the next 30–60 days; pair trade by going long 1% JNJ to capture defensive pharma exposure if headlines provoke wholesale sector derating.
• Reduce 5–10yr Treasury exposure to below 5% of portfolio and reallocate 2–5% into 2–5yr TIPS and cash/T-bills immediately if 10yr yield rises above 4.25% (signal of fiscal-driven curve repricing).
• Add 1–2% long exposure to NUE (Nucor) and XOM (Exxon Mobil) as a thematic play on infrastructure/energy demand; use a 3–6 month horizon and trim if commodity prices fail to rise by +5% within 90 days.
• Set explicit monitoring triggers: enter new longs only after committee markups or CBO score release in next 30–90 days; if Senate rules reduce chance of passage by >50% (per major aggregator), shift 50% of cyclical longs to cash within 5 trading days.